Zhonghong Pulin Medical Products Co., Ltd. Class A

Zhonghong Pulin Medical Products Co., Ltd. Class A

SSZSE:300981
14.00
CNY
-0.50
(-3.45%)
0.34EPS
58.66P/E
8.71BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.28
4.56
4.71
2.74
2.96
2.98
3.62
14.85
12.49
3.63
4.97
5.64
5.49
6.44
Basic EPS, GAAP
0.02
0.19
0.33
0.15
0.2
0.17
0.28
8.28
5.96
0.15
-0.31
-0.2
-0.26
0.35
Free Cash Flow per Basic Share
0.02
0.91
-0.22
0.16
0.06
-0.55
0.1
7.12
3.57
-0.23
-0.14
0.18
-0.43
- -
Dividend per Share
0.12
0.12
0.09
0.24
0.03
0.04
0.06
1.83
0.64
1.16
0.7
0.5
0.29
0.43
Book Value per Share
0.97
1.17
1.5
0.8
1
1.18
1.45
7.94
15.28
14.26
13.45
12.76
12.27
12.47
Tangible Book Value per Share
0.82
0.94
1.18
0.67
0.85
0.97
1.25
7.74
15.12
13.92
12.36
12.05
11.72
11.94
Basic Weighted Avg Shares
129
128
128
259
322
324
324
322
393
433
423
436
432
428
Sales/Revenue/Turnover
551
585
604
710
951
968
1,171
4,778
4,909
1,573
2,105
2,457
2,373
2,754
Operating Margin (%)
4.35
7.87
12.17
7.71
11.21
8.24
10.32
68.72
58.32
0.74
0.18
1.47
-2.25
11.69
Depreciation Expense
24
22
22
29
32
36
47
60
80
148
207
220
223
- -
Net Income, GAAP
3
25
42
38
65
57
89
2,664
2,342
67
-131
-87
-112
148
Effective Tax Rate (%)
24.31
25.08
26.21
27.34
25.36
20.62
13.57
16.55
15.89
- -
- -
- -
- -
12.85
Profit Margin (%)
0.55
4.26
7
5.38
6.83
5.86
7.62
55.74
47.7
4.26
-6.22
-3.55
-4.74
5.37
Working Capital
-85
-59
-52
-20
4
-120
-69
1,562
4,640
3,804
3,227
3,334
2,966
3,156
LT Debt
- -
- -
80
55
47
68
95
8
14
10
339
339
228
84
Total Equity
126
151
191
255
320
376
468
2,556
6,554
6,133
5,915
5,621
5,422
5,507
Return on Invested Capital (%)
- -
6.34
9.53
8.36
14.48
10.28
12.92
145.79
49.66
- -
- -
- -
- -
2.08
Return on Capital (%)
- -
9.29
13.54
11.08
22.05
19.38
24.48
154.94
50.75
- -
- -
- -
- -
2.61
Return on Common Equity (%)
- -
18.14
24.66
17
22.5
16.2
21.11
176.19
51.41
1.06
-2.2
-1.55
-2.09
2.76

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,491
1,391
1,571
LT Borrowings
120
181
64
LT Finance Leases
13
10
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
429
429
429
Market Capitalization
5,631
4,104
8,706

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,144
5,196
5,345
Cash, Cash Equivalents & STI
3,896
3,466
3,452
Accounts Receivable, Net
379
478
351
Inventories
697
672
701
Total Current Liabilities
2,215
2,053
2,189
Payables & Accruals
- -
- -
- -
ST Debt
1,491
1,391
1,571
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
68.5%
27.59%
-3.54%
Free Cash Flow
438.61%
-150.84%
-344.27%
Net Income, GAAP
257.97%
-81.84%
28.98%
Sales/Revenue/Turnover
36.43%
-3.61%
-3.4%
Total Cash Common Dividend
327.51%
-13.51%
-41.42%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
545
604
690
618
2,457
2025
629
608
- -
510
2,373
2026
602
876
766
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.07
0.04
-0.32
-0.2
2025
0.04
-0.03
- -
-0.25
-0.26
2026
0.01
0.36
0.22
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.48
0.02
- -
0.5
2025
0.01
0.24
- -
0.02
0.29
2026
0.02
0.37
0.02
- -
- -

Company Description

CEO
Jun Chen
Full Time Employees
3,884
Sector
Consumer non-durables
Industry
Apparel/Footwear
Address
Chengxi Park Tangshan HE China 063500
IPO Date
Apr 27, 2021
Business
Zhonghong Pulin Medical Products Co., Ltd. (300981.SZ) researches, develops, manufactures, and sells disposable medical consumables and equipment, focusing on health protection products, safe infusion systems, and innovation incubation solutions; its core offerings include nitrile gloves, PVC gloves, natural latex gloves, neoprene gloves, deproteinized gloves, medical radiation-proof gloves, anti-nuclear radiation gloves, wet gloves, double-layer two-color gloves, disposable exam gloves, surgical gloves, protective gloves, condoms, syringes, infusion sets, blood collection needles, indwelling needles, precision filter infusion sets, sterile dispensing syringes, vacuum blood-collecting vessels, portable electronic analgesic pumps, enteral nutrition pumps, infusion pumps, non-invasive temperature monitoring systems, disposable EEG electrodes, medical temperature sensors, blood pressure cuffs, and radial artery compression tourniquets. Founded in 2010 and headquartered in Tangshan, Hebei Province, China, the company operates five production bases across Tangshan (Hebei), Jiujiang and Yichun (Jiangxi), Guangyuan (Sichuan), Guilin (Guangxi), and Shenzhen (Guangdong), with subsidiaries in Beijing, Hong Kong, the United States, and the Netherlands; it maintains an annual production capacity exceeding 10 billion gloves and holds 225 patents as a national high-tech enterprise under Zhonghong Pulin Group, a core member of Fortune 500-listed Xiamen ITG Holding Group. Geographically, it serves medical, industrial, food, and healthcare sectors in China and international markets, ranking among China's top 500 listed medical device manufacturers. Recent developments include plans in 2024-2025 to invest 557 million yuan in the first phase of the SEA2 nitrile glove production base with 10 lines and the SEA1 project with 20 lines after terminating a prior medical-grade glove initiative in Sichuan for global strategy alignment; subsidiary products like enteral nutrition pumps, nasal cannulas, and injectors received registration certificates, renewals, and selections for regional bulk procurement; and in 2023, it completed the 58.8 million yuan acquisition of 70% stake in Shenzhen MedRena Biotech Co., Ltd.